tiprankstipranks
Trending News
More News >
Sarepta downgraded to In Line from Outperform at Evercore ISI
PremiumThe FlySarepta downgraded to In Line from Outperform at Evercore ISI
6d ago
Sarepta Therapeutics: Buy Rating Maintained Amid Growth Potential and Valuation Opportunity
Premium
Ratings
Sarepta Therapeutics: Buy Rating Maintained Amid Growth Potential and Valuation Opportunity
6d ago
Sarepta Therapeutics’ Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Sarepta Therapeutics’ Earnings Call: Growth Amid Challenges
7d ago
Sarepta price target lowered to $60 from $193 at Baird
PremiumThe FlySarepta price target lowered to $60 from $193 at Baird
7d ago
Sarepta price target lowered to $98 from $112 at Guggenheim
Premium
The Fly
Sarepta price target lowered to $98 from $112 at Guggenheim
7d ago
Long-Term Potential and Strategic Developments Drive Buy Rating for Sarepta Therapeutics Despite Short-Term Challenges
Premium
Ratings
Long-Term Potential and Strategic Developments Drive Buy Rating for Sarepta Therapeutics Despite Short-Term Challenges
7d ago
Sarepta price target lowered to $113 from $182 at Morgan Stanley
PremiumThe FlySarepta price target lowered to $113 from $182 at Morgan Stanley
7d ago
Sarepta price target lowered to $40 from $75 at H.C. Wainwright
Premium
The Fly
Sarepta price target lowered to $40 from $75 at H.C. Wainwright
7d ago
Buy Rating Maintained for Sarepta Therapeutics Despite Temporary Setbacks and Revised Guidance
Premium
Ratings
Buy Rating Maintained for Sarepta Therapeutics Despite Temporary Setbacks and Revised Guidance
7d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100